Lotte Bilogics, Excelgene and CDO business cooperation Memorandum of Understanding

Biospector Reporter Seo Yoon-seok

Collaborate to strengthen CDO and provide end-to-end CDMO services

Lotte Bilogics announced on the 4th that it has signed a memorandum of understanding (MOU) with Excelgene, a Swiss company specializing in cell line development, for CDO (contract development) business cooperation.

Under the agreement, the two companies cooperate in the process of end-to-end CDMO (contract development and manufacturing) services, from drug cell line development to large-scale shipment production, and can offer partnership jointly to potential customers who request it. .

Excelgene provides services such as cell line development and high yield process development, while Lotte Bilogics provides services such as Master Cell Bank service and clinical and commercial drug production. Details of the agreement were not disclosed.

Founded in 2001, Excelgene is a Swiss cell line development company that provides cell line development services to a number of clients, including major global pharmaceutical and bio companies. Excelgene has the ability to develop more than 100 GMP certified cell lines per year through its proprietary CHOExpress® and HEKExpress® cell platforms.

Lee Won-jik, CEO of Lotte Biologics, said, “In order to become a global CDMO company, it is important to improve CDO capabilities that require a lot of time and professional manpower.” We will continue to strengthen our competitiveness,” he said. He said.

Maria João Wurm, CEO of Excelgene, said, “This collaboration is the starting point for Excelgene to enter the US and Asian markets, and based on the expertise of both companies, we will provide the DNA-i solution -entire GMP for joint customers. .” he said.